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Summary During the last decade, the method of sputum induction (SI) has offered
the opportunity to study inflammation in patients with chronic obstructive pulmonary
disease (COPD). This paper reviews methodological aspects of SI and summarizes its
uses in the research of inflammation in COPD, including sputum cellularity and soluble
markers. SI is a relatively safe, reliable, and reproducible technique, used to
investigate different aspects of airway inflammation. Although various methods of
induction and processing have been proved safe and highly reproducible, a generally
accepted method is needed. Sputum analysis has given evidence for increased
numbers of macrophages and neutrophils in COPD patients compared to normal
subjects. In some studies, increased numbers of eosinophils have been also reported.
Changes in various mediators have been found in sputum supernatant of COPD
patients (IL-8, LTB-4 and TNF-a). The clinical usefulness of the method in the follow-
up of the disease has not been explored extensively. A number of observations in
patients with different clinical characteristics could be proven useful in identifying
patterns of inflammation associated with different prognosis. Finally, SI could also
guide treatment; such as, sputum eosinophilia in COPD could predict response to
inhaled corticosteroids.






The inhalation of an aerosol of hypertonic saline to
produce sputum was firstly used by Bickerman et al.
in 1958,1 in cytology of lung cancer. Later, induced
sputum (IS) was used for clinical purposes to detect
numerous pathogenic microorganisms.2–4 At the
beginning of 90s, sputum induction (SI) was
introduced by Pin and colleagues as a method to
study airway inflammation in asthma.5 Thereafter,
this method has been extensively used in the
field of research of airway inflammation and it
has considerably improved our understanding of
the most common pulmonary diseases, including




SI consists of inhaling an aerosol of saline produced
from an ultrasonic nebulizer. Due to the relative
invasiveness of this method, bronchodilation med-
ication, oxygen supply and resuscitation equipment
should be available. Although an experienced
technician can conduct SI, a physician should
supervise the procedure. The above limitations,
along with the relative high cost of the nebulizer,
probably limit the use of SI to specialized centers.
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Disagreement exists between various investiga-
tors on how the procedure of SI should be done and
on whether the entire sputum or just its plugs
should be collected and analyzed. This creates
confusion when data of sputum studies using
different methodology are compared. The European
Respiratory Society (ERS) has already set-up
a Task Force in an attempt to standardize SI,
sputum processing and analysis.6,7
Two are the main methods to induce sputum.
Iredal et al.8 propose the inhalation of the same
concentration of hypertonic saline (4.5%) for
increasing time intervals, while Pin et al.5 propose
the inhalation for the same period of increasing
concentrations of hypertonic saline (3%, 4%, 5%).
One study has shown that hypertonic saline 3% is as
successful in inducing sputum as hypertonic saline
3–5% given sequentially.9 In our laboratory, we use
the method of Pin et al.5 with a success rate more
than 95%, and without serious complications even
in severe COPD patients.10–13 Briefly, before the
beginning of the procedure, the baseline FEV1 is
recorded and an inhalation of MDI salbutamol
(200 mg) is given, followed by a spirometry 10min
later. It has been shown that b2 agonist pretreat-
ment has no effect on sputum inflammatory
percentages and ECP concentration in sputum,
however it decreases histamine concentration.9,14
Then SI is performed. The subject inhales hyper-
tonic saline for maximum 10-min sessions. The
concentration of the inhaled saline is consecutively
increased in each session from 3% to 4% and to 5%.
Always between sessions the inhalation procedure
is interrupted and the subjects are asked to blow
their nose, rinse their mouth and try to expectorate
sputum into a sterilized box. By this way saliva
contamination of the sample is minimized and
percentage of squamous cells in the sample is
decreased.15 The best quality of samples is
achieved by using controlled exhalation and
coughing effort. Expectoration of secretions by
sniffing or gargling should be avoided. This stage is
very crucial to select samples representative
of the airways secretions. Between inhalation
sessions a spirometry is always performed to
detect significant fall of FEV1. The procedure is
stopped when an adequate sputum sample is
collected (approximately 1 g of plugs), or if
troublesome symptoms have been presented or/
and if FEV1 falls more than 20% of the baseline
measure observed. It is not clear by which
mechanism the inhalation of hypertonic saline
produces sputum. An osmotic effect16,17 or an
increase in mucocilliary clearance18,19 and/or
stimulation of glandular secretions is the proposed
explanation.
Sputum processing
The sputum should be processed within the next
30min or no more than 2 h, with the sample always
kept in ice. Numerous laboratories prefer to
process the entire sputum, a method introduced
by Fahy et al.20 Others prefer to collect and analyze
the more viscid proportions of the sputum (plugs),
as described by Pin et al.5 and modified by Popov
et al.9 Both procedures have been shown to be valid
and reproducible, but the method of selected
sputum-plugs provides higher cell viability and
quality.21,22
Briefly, after the selection and weighing of
sputum plugs, dithiothreitol (DTT) is added, fol-
lowed by Dulbecco’s phosphate buffer saline
(D-PBS). Then, the mixture is filtered and centrifuged.
The supernatant is aspirated and frozen at 801C
for analysis later. The cell pellet is resuspended
with D-PBS plus 10% FCS (fetal calf serum). A total
cell count (TCC) of the filtered sample is always
performed, preferentially before centrifugation23
and viability is tested by means of trypan blue
exclusion method. If cell viability is less than 50%
and/or squamous cell contamination is more than
20%, the sample cannot be used because results
have been shown to be less reproducible.24 Sputum
cell suspensions are kept into eppendorf cups.
Cytospins are also prepared. Both are kept at
801C for later processing. Differential cell counts
(DCC) are usually performed on May-Grunwald
Giemsa stained cytospins, excluding squamous
epithelial cells.
In the first step of sputum processing, DDT is
added. DDT is a reducing agent destructing mucus
glycoproteins and is used to liquefy and to homo-
genize sputum. However, DDT could destroy im-
portant cell surface markers (epitopes) and other
free soluble molecules (mediators). It might also
interfere with the capture antibodies of immunoas-
says. Various studies have shown the effect of DDT
on cell viability,25 on lymphocyte, eosinophilic,
neutrophilic markers26–29 and on soluble media-
tors.30,31 Consecutively, the DDT effect on the
marker of interest should always be considered.
Flow-cytometry
Some cellular markers can be analyzed right away,
if the sample is processed to flow cytometry.
Briefly, sputum cells (approximately 1 million cells)
are treated with albumin for 10min and then with
the antibodies chosen for 30min at 371C. The
mixture washed twice with D-PBS is ready for
analysis. If treated with formaldehyde it can
be analyzed within the next 1–2 days. In our
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laboratory samples prepared as described above
are analyzed on an EPICS ELITE fluorescence
activated flow-cytometer as follows.10,11,13,32 The
cells are tightly gated by volume and complexity on
a forward (01) and side light scattering (901) mode.
The appropriate control is always used for subtrac-
tion of the background. The percentage of one-,
two- or three-color positive cells is measured and
the mean channel value (MCV) as well as the
relative fluorescence intensity (RFI) corresponding
to the antigen density is estimated. The QC-Combo
Kit (FCSC, San Juan, USA) is used for quantification
of antibody binding. The number of positive cells in
gated cell populations that are stained with the
labeled antibody/antibodies is measured and ex-
pressed as percentage of gated cells. Day-to-day
instruments calibration (amplification and compen-
sation settings of the flow cytometer) is routinely
followed.
This method allows the simultaneous staining of
cells with different markers and, therefore, can be
used to analyze cellular subtypes or cellular
activation.33 However, until nowadays it cannot
separate eosinophils from neutrophils with accu-
racy.34 On the contrary, it is preferred for lympho-
cyte analysis in sputum samples. Sputum usually
contains very low numbers of lymphocytes (1–2%).
For this reason, we analyze approximately 1 million
of sputum cells, among which there should be at
least 10 000 lymphocytes. Using flow-cytometry we
have recently analyzed sputum T-lymphocytes
subsets and intracellular expression of perforin in
sputum CD8þ T-lymphocytes.10,11,13,32 Lympho-
cytes can be difficult to gate from other cells,
unless gated by volume and complexity and by
CD45þ expression (pan leukocyte marker).32 The
use of anti-CD45 antibody (monoclonal mouse anti-
human) is most crucial, because it allows the
differentiation of epithelial cells from lympho-
cytes. Figures 1 and 2 clearly demonstrate the
difference in the quality of data obtained with and
without anti-CD45 antibody use. The following
mouse anti-human monoclonal antibodies are suc-
cessfully used in our laboratory for labeling sputum
lymphocyte cells: anti-CD3, anti-CD4 and anti-CD8,
anti-perforin, as well as unlabelled anti-human-
perforin for intracellular perforin detection. The
above antibodies are peridin chlorophyll protein
(PerCP)-, phycoerythrin-cyanine (PCy-5), or FITC-
conjugated. Mouse anti-mouse isotype matched
PerCP-, Pcy-5-, or FITC-conjugated immunoglobu-
lins are, therefore, used as control antibodies.
In general, following the above method we can
obtain clear data in about 90% of our sputum
samples. In the remaining 10% we fail to analyze
sputum lymphocytes due to their extremely low
number in some samples (o1%), or because of
their destruction during sputum processing.
Reproducibility
There have been studies showing that sputum cell
counts are highly reproducible both within investi-
gator and between investigators,35,36 with the








Figure 1 Histogram of sputum cells from a COPD
patient. The CD45 expression was not used for gating
lymphocytes. Gating of lymphocytes is impossible. FS:








Figure 2 Histogram of the same sputum cells, using the
CD45 expression for gating lymphocytes. Gating of
lymphocytes is possible (circle). FS: forward scattering
mode, SS: side light scattering mode.
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and squamous cell contamination low.37 Highly
reproducible results have been also reported in
studies examining sputum samples from the same
individual induced on different days.35,36,38–41
However, other investigators showed that con-
secutive samples of IS might differ with respect to
cellular composition.42,43 Nightingale et al., have
recently reported that repeated induced sputum in
healthy volunteers within 8 or 24 h, showed con-
siderable increases in neutrophil counts and per-
centages.42 According to the authors this
observation is attributed to an inflammatory
response of the airways to the induction procedure.
There is accumulating evidence, from studies in
normal subjects as well as in asthmatics, that high
saline concentration induces airway neutrophi-
lia.44–46 A high decrease in the time interval
between two sputum samples may significantly
influence the results.44–46 Indeed different samples
obtained at different inhalation periods differ with
respect to cell differentiation and fluid phase
markers.44 Furthermore, differences are observed
depending on the type and the severity of the
disease.46 These data have led to the hypothesis
that repeated SI within a time scale of 40min
constitute of samples from different parts of
bronchial tree. Some evidence suggests that the
initial samples possibly represent the more central
airways, while the last ones, the more peripheral
ones.44,45 If such a hypothesis is confirmed, then
the duration of the induction procedure should be
standardized and always mentioned in a study.
Safety in COPD
It is known that SI may provoke bronchoconstric-
tion. Various mechanisms may be involved in the
observed bronchoconstriction; the hypertonicity of
the saline, the total inhaled amount, the rate of
delivery.9,43,47 Although several studies assess the
safety of IS in asthma,48–50 there is little informa-
tion concerning COPD. One study reports no side
effects of the procedure in COPD patients,35 while
three others report clinically important dyspnea
and/or fall in FEV1 410% in a number of patients,
ranging from 15% to 47%.38,51,52 Patients whose
airway obstruction is more reversible seem to be
better protected by bronchodilator pretreat-
ment.51 These results indicate the necessity of
monitoring spirometry of a COPD patient during the
SI procedure in order to detect on time airway
constriction. In our laboratory with any fall in FEV1
between 10% and 20% of baseline we do not
proceed to an increase in the concentration of
saline, while if we detect a 20% fall, we stop the
procedure. We have performed more than two
hundred SI in moderate and severe COPD patients
without significant clinical side effects.10–13 In
general, the risks from SI in patients with COPD
are acceptable.
Inflammatory indices in COPD obtained
by sputum analysis
Inflammatory cells
Sputum analysis has shown that in the airway lumen
of patients with COPD, the neutrophil is the
predominant cell. Increased numbers of neutrophils
have been found in sputum samples of stable COPD
patients.53–57 Moreover, a negative correlation has
been reported between the percentage of neutro-
phils and FEV1.
35,55,58 The neutrophilic inflamma-
tion partly explains the resistance of most COPD
patients to steroid treatment,59 though some
investigators report a decrease in the neutrophilic
counts after steroid treatment.60,61
Another cell, which recently has gained much
attention for its potential involvement in COPD
pathogenesis, is the macrophage. Though sputum
samples in COPD patients contain less macrophages
than neutrophils, investigators have used sputum
analysis to study the role of macrophage metallo-
proteinases in tissue remodeling and airway
obstruction.62–64
Sputum analysis also involves the eosinophil in
COPD pathogenesis. Saetta et al. report increased
sputum eosinophil numbers on COPD exacerba-
tions.65 Other investigators do not confirm this
finding.66 However, many studies have demon-
strated sputum eosinophilia (sputum eosino-
philsX3%) in COPD patients under stable
conditions,67–70 as well as an inverse correlation
between the number of sputum eosinophils and
FEV1 value.
67,68 This is also a clinically relevant
observation since COPD patients with sputum
eosinophilia respond better to treatment with
inhaled steroids.69,70 Controversy exists on whether
eosinophils in COPD are activated or not.67,68
Although sputum samples are rich in neutrophils,
eosinophils and macrophages, they contain rela-
tively small numbers of lymphocytes. These cells
have been extensively studied in bronchial biopsy
specimens and bronchoalveolar lavage fluid (BALF)
from patients with COPD, but not in sputum. BALF
and biopsy studies showed an increase in the
total numbers of T-lymphocytes, with the predo-
minance in the CD8þ ve cytotoxic T-cells.71–73 In
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our laboratory, lymphocytes in sputum and their
subpopulations were investigated by using flow-
cytometry, or by isolating lymphocytes from spu-
tum samples and proceeding to immunocytochem-
ical analysis. By using these methods, we achieved
to measure T-lymphocyte subpopulations. A de-
crease in the CD4/CD8 ratio, as well as a decrease
in the Tc1/Tc2 ratio (Tc1 and Tc2 cells are
subpopulations of CD8þ ve cells) in COPD smokers
compared to healthy smokers, was observed.10,11
Moreover, an increase in perforin, which is released
by CD8 cells and causes cytolysis, was found.13
Inflammatory mediators
The inflammatory process of COPD is complex. It
involves not only inflammatory cells, but also
certain mediators, which interact with each other
and with the relevant cells. Nowadays numerous
inflammatory mediators are being measured in the
fluid phase of sputum. The precision and validity of
these measurements greatly depends on the assay,
on the mediator measured, on the nature of sputum
itself, as well as on the effect of sputum processing
on both the mediator measured or the antibodies
used. Unfortunately, the standard mediator used in
an immunoassay might differ from the endogenous
mediator and from the standard mediator in
another assay, making comparisons between differ-
ent assays invalid. An effort is being done to
standardize different assays, so that valid compar-
isons can be done.74
Despite the above considerations, it is accepta-
ble to measure mediators in sputum supernatant,
as long as attention is given to the method of
measurement and results are carefully interpreted.
Keatings et al., have shown that sputum samples
from COPD patients are characterized by an
increase in eosinophilic cationic protein (ECP) and
eosinophil peroxidase (EPO), which are the major
eosinophilic granule proteins, as well as in myelo-
peroxidase (MPO) and human neutrophil lipocalin
(HNL), which are both neutrophilic granule pro-
teins.59 These findings suggest that neutrophils, as
well as eosinophils, are activated in COPD patients.
Moreover, leukotriene B-4 (LTB-4), which is che-
moattractant to neutrophils, has been recently
reported increased in the sputum of patients with
COPD.75 Tumor necrosis factor-a (TNF-a), a proin-
flammatory cytokine known to up regulate adhesion
molecules, and interleukin-8 (IL-8), a potent
neutrophil attractant, both have been reported to
be elevated.55 The levels of both chemoattractants
of neutrophils (IL-8 and LTB-4) correlate positively
to MPO and neutrophi elastase (NE).76 In the same
direction, lower sputum levels of IL-10, a cytokine
known to down regulate inflammatory responses,
have been found in COPD patients.77 A lower level
of IL-10 positive cells was also reported in the same
study.77
Sputum analysis makes possible the study of
mediators involved in the pathogenesis of COPD
exacerbations. Increased levels of IL-8 and TNF-a
have been observed during an acute exacerbation
of COPD, independently of airway infection.78
According to the results of a study by Bhowmik
et al., high IL-6 and IL-8 levels in stable COPD are
related to high frequency of exacerbations.66 In the
same study, the analysis of sputum samples
obtained on an exacerbation revealed high levels
of IL-6, a cytokine known to promote immunoglo-
bulin production. Interestingly, these levels related
to the presence of a ‘‘common cold’’ and to the
eosinophil and lymphocyte numbers. In contrast,
Gompertz et al., in a recent study reported no
relationship between baseline levels of numerous
mediators such as IL-8, MPO, leucotriene B-4 (LTB-
4) and secretory leucoproteinase inhibitor (SLPI),
and frequency of exacerbations.79 Finally, endothe-
lin-1 (ET-1), a bronchoconstrictor peptide, has been
reported to be increased in sputum samples of
COPD patients during an exacerbation.80 In conclu-
sion, in either stable or exacerbated COPD, several
inflammatory mediators are measured in induced
sputum. This indicates that a complex interaction
between cells and mediators takes part in the
progressive obstructive deterioration in the small
airways and in the destruction of lung parenchyma
observed in COPD patients.54
Comparison of induced sputum with
spontaneous sputum, BAL and bronchial
biopsies
Spontaneous sputum, IS, BALF, bronchial biopsies
and surgical specimens are the common methods to
study lung inflammation. Surgical specimens ex-
ceed all others in that they offer the chance of
studying structure, as well as inflammation of the
entire lung, airways, arteries and parenchyma.
Still, difficulties in their acquisition and analysis
have made them the least used method. Sponta-
neous sputum samples, though completely safe, are
also rarely studied because they contain less viable
cells than IS samples.52,81 Interestingly, no differ-
ence has been found in inflammatory cells41,52 and
IL-852 between spontaneous and IS. Pizzichini et al.,
in a study in asthmatic patients showed that a
viability of the spontaneous sample higher than 50%
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predicts the agreement between fluid phase mar-
kers.41 Possibly, in cases when SI cannot be safely
applied, like in COPD exacerbations, spontaneous
sputum samples could be an acceptable alterna-
tive, but this has to be proven.
Although IS may show the same inflammatory
profile with spontaneous sputum, differences are
observed compared to BALF or biopsies. Studies in
COPD patients have shown that sputum, BALF and
bronchial biopsies represent different lung com-
partments.57,82 Sputum mainly originates from the
large airways, bronchial biopsies from the large or
small airways depending on the site chosen and
BALF from the bronchioles and alveoli. In COPD
sputum consists mainly of neutrophils, while it has
less macrophages and even less lymphocytes. BALF,
on the other hand, consists mainly of macrophages,
with less neutrophils and lymphocytes. Interest-
ingly, sputum has the advantage of a more
concentrated sample and contains more cells, as
well as more fluid-phase markers than BALF.83 In
biopsies, the lymphocyte is the predominant cell,82
while there is no great difference in eosinophils
between sputum, BALF and biopsy specimens.82
Same observations have been also made in respec-
tive studies in asthmatic subjects.83–85
Clinical applications
As shown earlier, sputum analysis gives evidence for
a close association between airway inflammation
and COPD pathogenesis. In this light SI could be
used in clinical practice for the assessment of
airway inflammation in COPD. Moreover, it is
possible that different sputum inflammatory pro-
files are connected to different disease pheno-
types. For example, sputum eosinophilia has been
found characteristic of patients with steroid re-
sponse and sputum analysis might serve as a
screening test before deciding on long-term corti-
costeroid treatment in COPD. Although SI has much
potential to develop as a clinical tool (it is a simple,
safe and well-tolerated method) convincing data
for any usefulness in clinical practice is lacking.
Once this method is introduced for routine assess-
ment of COPD patients the issue of cost effective-
ness has to be considered as well.
Conclusion
In conclusion, SI is a relatively reliable and safe
method to study airway inflammation in COPD.
These unique characteristics make it a useful tool
in the investigation of the complex inflammatory
processes of COPD. So far, it has showed interac-
tions between inflammatory cells and mediators,
which are related to physiological consequences of
obstruction. On the other hand, sputum analysis
could be used in clinical practice as a monitoring or
screening test. Considering the importance of the
above method in the research and its possible
clinical applications, a further development of the
technique is expected. This includes standardiza-
tion and introduction of methods to investigate
new markers of inflammation. The use of flow-
cytometry could also enhance the applications
of SI.
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